Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Capital Employed (2017 - 2025)

Protagonist Therapeutics' Return on Capital Employed history spans 9 years, with the latest figure at 0.25% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 65.0% year-over-year to 0.25%; the TTM value through Dec 2025 reached 0.25%, down 65.0%, while the annual FY2025 figure was 0.24%, 74.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.25% at Protagonist Therapeutics, down from 0.03% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.5% in Q1 2024 and bottomed at 0.66% in Q1 2023.
  • The 5-year median for Return on Capital Employed is 0.26% (2021), against an average of 0.17%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 116bps in 2024 before it plummeted -65bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.4% in 2021, then plummeted by -41bps to 0.56% in 2022, then soared by 91bps to 0.05% in 2023, then soared by 885bps to 0.4% in 2024, then plummeted by -161bps to 0.25% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Return on Capital Employed are 0.25% (Q4 2025), 0.03% (Q3 2025), and 0.03% (Q2 2025).